Full text is available at the source.
Abstract
Therapeutic levels of OTC protein expression are achieved with minimal toxicity in preclinical models using optimized mRNA-LNP formulations.
- Lipid nanoparticle formulations influence how therapeutics are distributed in the body and taken up by cells.
- A novel helper lipid, 1,2-dierucoyl-sn-glycero-3-phosphoethanolamine (DEPE), enhances liver-specific delivery by modulating lipid structure and apolipoprotein E binding.
- A new ionizable lipid with an N-(2-Hydroxyethyl)piperazine-N'-(4-butanesulfonic acid) (HEPBS) core allows for cellular uptake independent of the low-density lipoprotein receptor pathway.
- The optimized formulations show robust dose responsiveness and sustained therapeutic expression.
- Minimal toxicity is indicated by stable liver function markers and cytokine levels.
Simplified